• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Pharma Pulse 11/15/24: SARS-CoV-2 Infection Impact Child Neurodevelopment, History of ED Increases Risk of Psychiatric Disorders for Children & more

News
Article

The latest news for pharma industry insiders.

Does Prenatal Exposure to the SARS-CoV-2 Infection Impact Child Neurodevelopment?

Investigators explore this potential association, including how it affects a child’s first two years of life.

Risk of Psychiatric Disorders Increases for Children of Mothers With Eating Disorder History

During pregnancy, maternal nutrition is significant in fetal development. Particularly, neurodevelopment is a very regulated process that can be influenced by both internal and external factors. Because of this, irregular or disordered eating may also contribute to the offspring’s development. Authors of a study published in JAMA Network Open expanded on existing associations between different maternal eating disorders and pre-pregnancy body mass index (BMI) with neurodevelopmental and psychiatric diagnoses in offspring. Additionally, the authors assessed potential differences between exposure to maternal anorexia nervosa (AN) compared with maternal underweight with offspring mental health.

Merck Snags Chinese Cancer Drug For Up to $3.3 Billion

Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront, plus as much as $2.7 billion in milestone payments.

Olfactive Biosolutions Begins Production of Patented GLP-1/GIP Weight Loss and Blood Sugar Reduction Supplement

Olfactive Biosolutions, the leader in harnessing food molecules for the treatment of chronic diseases, has begun production of its Protenx™ GLP-1/GIP Weight Loss patented weight loss and blood sugar reduction formulation under its U.S. patent US 12,102,664.

ClinicalMind on LinkedIn

Feeling grateful this morning for an opportunity to be part of Pharmaceutical Executive APEX awards and especially thankful for our team and what they've achieved. We really do believe a winning formula in creative is bringing together people who genuinely enjoy working with one another, trusting the diverse talents each individual brings to the table, and weaving these together into bold and innovative solutions.

Congrats to all the nominees and winners! 🏆

#APEXAwards #ClinicalMind #HealthcareInnovation

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs